prikaz prve stranice dokumenta Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
  Preuzmi
PDF 571.52 KB
Znanstveni rad - Izvorni znanstveni rad
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Frontiers in Immunology, 14 (2023); 1252811. https://doi.org/10.3389/fimmu.2023.1252811
Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Sanderson, Robin; Yakoub-Agha, Ibrahim; Fegueux, Nathalie; Daskalakis, Michael; Collin, Matthew; Dreger, Peter; Kröger, Nicolaus; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Besley, Caroline; Wulf, Gerald G.; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W.; Chabannon, Christian; Sureda, Anna; Glass, Bertram; Perić, Zinaida Više autora...

Citirajte ovaj rad

Penack, O., Peczynski, C., Koenecke, C., Polge, E., Sanderson, R., Yakoub Agha, I. ... Perić, Z. (2023). Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in Immunology, 14.. doi: 10.3389/fimmu.2023.1252811

Penack, Olaf, et al. "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party." Frontiers in Immunology, vol. 14, 2023. https://doi.org/10.3389/fimmu.2023.1252811

Penack, Olaf, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Robin Sanderson, Ibrahim Yakoub Agha, Nathalie Fegueux, et al. "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party." Frontiers in Immunology 14 (2023). https://doi.org/10.3389/fimmu.2023.1252811

Penack, O., et al. (2023) 'Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party', Frontiers in Immunology, 14. doi: 10.3389/fimmu.2023.1252811

Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub Agha I, i sur.. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in Immunology [Internet]. 27.09.2023. [pristupljeno 12.07.2024.];14. doi: 10.3389/fimmu.2023.1252811

O. Penack, et al., "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party", Frontiers in Immunology, vol. 14, Rujan 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:165258. [Citirano: 12.07.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:165258
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
AutorOlaf Penack
AutorChristophe Peczynski
AutorChristian Koenecke
AutorEmmanuelle Polge
AutorRobin Sanderson
AutorIbrahim Yakoub-Agha
AutorNathalie Fegueux
AutorMichael Daskalakis
AutorMatthew Collin
AutorPeter Dreger
AutorNicolaus Kröger
AutorUrs Schanz
AutorAdrian Bloor
AutorArnold Ganser
AutorCaroline Besley
AutorGerald G. Wulf
AutorUrban Novak
AutorIvan Moiseev
AutorHélène Schoemans
AutorGrzegorz W. Basak
AutorChristian Chabannon
AutorAnna Sureda
AutorBertram Glass
AutorZinaida Perić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Immunology
Brojčani podacivol. 14, 1252811
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2023.1252811
URN:NBNurn:nbn:hr:105:165258
Datum objave publikacije2023-09-27
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1252811/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-05-17 08:38:20